Clinical trials: Polyposis
Chronic Rhinosinusitis With Nasal Polyposis
A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2）
This is an open-label, single-arm, multicenter, extension study to evaluate the safety and efficacy of CM512 in patients With Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- NCT07519577
- Testing
- CM512
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Keymed Biosciences Co.Ltd
Adenomatous Polyposis Coli
A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis
The purpose of this study is to determine the effect of JNJ-64251330 in participants with Familial Adenomatous Polyposis (FAP) on colorectal polyp burden (sum of the polyp diameters).
- Trial name
- NCT05014360
- Testing
- JNJ-64251330
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Angelman Syndrome, Chromosome 15q Duplication (dup15q) Syndrome
Angelman Syndrome (AS) Biomarker Study
The primary objective of this study is to measure ubiquitin-protein ligase E3A (UBE3A) protein levels in cerebrospinal fluid (CSF) and to evaluate its utility as a biomarker in support of the development of therapies for AS.
- Trial name
- NCT04103333
- Testing
- Lumbar Puncture, Blood Collection
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Biogen
Bilateral Nasal Polyposis
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects…
- Trial name
- NCT01624662
- Testing
- Fluticasone propionate
- Where
- 10 sites in United States
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyposis
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal…
- Trial name
- OPALE (NCT06393946)
- Testing
- Dupilumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
This is a multicentre, open-label, single-arm, Phase 3b study to assess nasal polyps score and symptoms in Chinese adult participants with chronic rhinosinusitis with nasal polyposis initiating treatment with tezepelumab.
- Trial name
- BIFANG (NCT07520162)
- Testing
- Tezepelumab
- Where
- 34 sites in China
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Healthy Volunteers
A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers
A pharmacokinetic study in healthy volunteers to determine the relative bioavailability of three formulations of celecoxib to the approved formulation.
- Trial name
- NCT00813241
- Testing
- celecoxib reference formulation, celecoxib test formulation A1, celecoxib test formulation B2
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Familial Adenomatous Polyposis (FAP)
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compare eRapa to Placebo.
- Trial name
- SERENTA (NCT06950385)
- Testing
- eRapa (encapsulated rapamycin)
- Where
- 29 sites in United States, Denmark and 5 more
- Volunteers
- 168 people
- Sponsor
- Rapamycin Holdings Inc.
Adenomatous Polyposis Coli
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
- Trial name
- NCT00140894
- Testing
- MK0966; rofecoxib / Duration of Treatment: 24 weeks
- Volunteers
- 62 people
- Sponsor
- Merck Sharp & Dohme LLC
Nasal Polyposis
Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with…
- Trial name
- OSTRO (NCT03401229)
- Testing
- Benralizumab 30 mg SC + Mometasone Furoate
- Where
- 99 sites in United States, Austria and 6 more
- Volunteers
- 413 people
- Sponsor
- AstraZeneca
Bilateral Nasal Polyposis
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis
- Trial name
- NCT03688555
- Testing
- ACT-774312
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 10 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Bilateral Nasal Polyposis
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a…
- Trial name
- NCT03747458
- Testing
- OPN-375
- Where
- 31 sites in United States, Argentina
- Volunteers
- 40 people
- Sponsor
- Optinose US Inc.
Nasal Polyposis
Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video
This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video.
- Trial name
- NCT03591068
- Testing
- Fluticasone Propionate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis With Nasal Polyposis
Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
The primary objectives of the study are: To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic…
- Trial name
- AROMA (NCT04959448)
- Testing
- DUPIXENT®
- Where
- 81 sites in United States, Canada and 4 more
- Volunteers
- 717 people
- Sponsor
- Regeneron Pharmaceuticals
Ulcerative Colitis, Familial Polyposis
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery
This will be a prospective, multi-center, randomized, single blind study to collect and evaluate post-market clinical data on the SprayShield Adhesion Barrier System as an adjuvant to good surgical technique for the reduction of…
- Trial name
- NCT01002287
- Testing
- SprayShield Adhesion Barrier System, Good Surgical Technique Alone
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Integra LifeSciences Corporation
Chronic Rhinosinusitis With Nasal Polyps
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1.
- Trial name
- ESSENCE (NCT06706817)
- Testing
- Tezepelumab
- Where
- 41 sites in United States, Bulgaria and 7 more
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Bilateral Nasal Polyposis
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral…
- Trial name
- NCT01622569
- Testing
- Fluticasone Propionate
- Where
- 33 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Nasal Polyps
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.
- Trial name
- NCT01920893
- Testing
- Dupilumab, Mometasone furoate nasal spray
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Chinese Adult Participants With CRSwNP
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult participants with CRSwNP, on a background therapy…
- Trial name
- NCT05878093
- Testing
- Dupilumab, Budesonide
- Where
- 18 sites in China
- Volunteers
- 63 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and…
- Trial name
- SINUS-52 (NCT02898454)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate nasal spray
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 448 people
- Sponsor
- Sanofi